ObsEva SA - Company Profile
Powered by
All the data and insights you need on ObsEva SA in one report.
- Save hours of research time and resources with
our up-to-date ObsEva SA Strategy Report
- Understand ObsEva SA position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
ObsEva SA (ObsEva) is a clinical-stage biopharmaceutical company that develops and commercializes drugs for women’s reproductive health and pregnancy. The company's product portfolio comprises pipeline products for controlling preterm labor by reducing inflammation, decreasing uterine contractions, and preventing cervical changes and membrane ruptures; for the treatment of pain in association with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women and to decrease contractions, improve uterine blood flow and enhance the receptivity of the endometrium to the embryo implantation. ObsEva is headquartered in Geneva, Switzerland.
ObsEva SA premium industry data and analytics
Products and Services
Products |
---|
Pipeline Products |
Nolasiban : |
IVF |
XYZ |
XYZ |
XYZ |
Competitor Comparison
Key Parameters | ObsEva SA | Myovant Sciences Inc | Ferring Holding SA | Stragen Pharma SA |
---|---|---|---|---|
Headquarters | Switzerland | United States of America | Switzerland | Switzerland |
City | Plan-Les-Ouates | Brisbane | St-Prex | Geneva |
State/Province | - | California | - | Genf |
No. of Employees | 15 | - | - | 150 |
Entity Type | Public | Private | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Annette Clancy | Chairman | Executive Board | 2022 | - |
Fabien de Ladonchamps | Chief Executive Officer | Senior Management | 2023 | - |
Will Brown | Chief Financial Officer | Senior Management | 2022 | - |
Katja Buhrer | Chief Strategy Officer | Senior Management | 2022 | - |
Jean-Pierre Gotteland, Ph.D. | Chief Scientific Officer; Head - R&D | Senior Management | 2015 | - |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer